Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06996080 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

Study acronym: PINNACLE
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 150 to 300v3 Show 5 more changesShow less
    • Study sites: 33 to 56
    • Primary completion date: Dec 2026 to Feb 2027
    • Study completion date: Jul 2027 to Aug 2027
    • Eligibility criteria expanded, about 28 words
    • Secondary endpoints expanded, about 6 words
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 33
    • Start date changed from estimate of Jul 2025 to Jul 16, 2025
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
Trial Details
NCT Number NCT06996080
Lead Sponsor Kodiak Sciences Inc
Conditions
(from sponsor)		 Macular Edema Secondary to Inflammation
Related terms Macular Edema
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov